The article describes a trend in which drug labels are used as evidence of patent infringement in pharmaceutical disputes. In the US, original drug manufacturers register method patents in the Orange Book, which allows generic companies to be accused of induced infringement if their labels contain similar indications. An example is the dispute over carvedilol (Coreg), where Teva amended the label in 2011 to include an indication for heart failure after one patent expired. Firms such as GSK accuse generic companies of actively inducing doctors to infringe patents under Section 271(b) of the US Patent Act. This approach complicates the so-called skinny labeling, where generics omit patented indications. The trend leads to delays in the entry of generics into the market, which increases costs and limits patients' access to cheap drugs.[2][3]